Literature DB >> 17086572

An analysis of the psychometric profile and frequency of anxiety and depression in Australian men with prostate cancer.

Christopher F Sharpley1, David R H Christie.   

Abstract

Zung's Self-Rating Anxiety Scale and Self-Rating Depression Scale were used to collect data from 195 Australian men who had received a diagnosis of prostate cancer. Analysis was via separate scales and also by combining both scales into a single unit to assess anxiety-depression and then analysing the underlying component structure of that unit. Applying Zung's recommended cutoff scores, 12% of the sample were classified as having clinically significant levels of anxiety and 16% had similar levels of depression. Factor analysis of the combined SAS and SDS indicated four major components which reflected a process of: loss of functional capacity, worthlessness and hopelessness, fear and somatic symptomatology. Implications for the effective assessment and treatment of anxiety and depression in prostate patients are discussed. Copyright 2006 John Wiley & Sons, Ltd.

Entities:  

Mesh:

Year:  2007        PMID: 17086572     DOI: 10.1002/pon.1118

Source DB:  PubMed          Journal:  Psychooncology        ISSN: 1057-9249            Impact factor:   3.894


  17 in total

1.  Psychosocial interventions to improve quality of life in prostate cancer survivors and their intimate or family partners.

Authors:  Terry A Badger; Chris Segrin; Aurelio J Figueredo; Joanne Harrington; Kate Sheppard; Stacey Passalacqua; Alice Pasvogel; Maria Bishop
Journal:  Qual Life Res       Date:  2010-12-19       Impact factor: 4.147

2.  Reversible changes in brain glucose metabolism following thyroid function normalization in hyperthyroidism.

Authors:  Q Miao; S Zhang; Y H Guan; H Y Ye; Z Y Zhang; Q Y Zhang; R D Xue; M F Zeng; C T Zuo; Y M Li
Journal:  AJNR Am J Neuroradiol       Date:  2011-05-19       Impact factor: 3.825

3.  Who benefits from a psychosocial counselling versus educational intervention to improve psychological quality of life in prostate cancer survivors?

Authors:  Terry A Badger; Chris Segrin; Aurelio J Figueredo; Joanne Harrington; Kate Sheppard; Stacey Passalacqua; Alice Pasvogel; Maria Bishop
Journal:  Psychol Health       Date:  2012-10-09

4.  The effects of low- and high-dose-rate brachytherapy on depressive symptoms in prostate cancer patients.

Authors:  Christopher F Sharpley; David H R Christie; Vicki Bitsika; Andrew J Oar
Journal:  Int J Clin Oncol       Date:  2013-12-17       Impact factor: 3.402

5.  Comparing a genetic and a psychological factor as correlates of anxiety, depression, and chronic stress in men with prostate cancer.

Authors:  Christopher F Sharpley; David R H Christie; Vicki Bitsika; Nicholas M Andronicos; Linda L Agnew; Timothy M Richards; Mary E McMillan
Journal:  Support Care Cancer       Date:  2018-03-30       Impact factor: 3.603

6.  Quality of life of men treated for localized prostate cancer: outcomes at 6 and 12 months.

Authors:  Elise L Lev; Lucille Sanzero Eller; Glen Gejerman; John Kolassa; Joan Colella; Janine Pezzino; Patricia Lane; Ravi Munver; Michael Esposito; John Sheuch; Vincent Lanteri; Ihor Sawczuk
Journal:  Support Care Cancer       Date:  2008-08-22       Impact factor: 3.603

7.  Psychological Distress among Prostate Cancer Patients: Fact Or Fiction?

Authors:  Christopher F Sharpley; Vicki Bitsika; David H R Christie
Journal:  Clin Med Oncol       Date:  2008-12-16

8.  The role of Melancholia in prostate cancer patients' depression.

Authors:  Christopher F Sharpley; Vicki Bitsika; David R Christie
Journal:  BMC Psychiatry       Date:  2011-12-20       Impact factor: 3.630

9.  The Anxiety Depression Pathway Among Men Following a Prostate Cancer Diagnosis: Cross-Sectional Interactions Between Anger Responses and Loneliness.

Authors:  Simon M Rice; David Kealy; John S Ogrodniczuk; Zac E Seidler; Gabriela Montaner; Suzanne Chambers; John L Oliffe
Journal:  Am J Mens Health       Date:  2021 May-Jun

Review 10.  Depression and prostate cancer: implications for urologists and oncologists.

Authors:  Christopher F Sharpley; David R H Christie; Vicki Bitsika
Journal:  Nat Rev Urol       Date:  2020-07-30       Impact factor: 14.432

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.